Global Cancer Diagnostics Market: Industry Perspective, Analysis, Size, Share, Growth, Segment & Forecast, 2014 – 2020

Cancer Diagnostics Market by Methods (Tumor Biomarker Tests, Imaging, Endoscopy, and Biopsy) for Blood Cancer, Breast Cancer, Colorectal Cancer (CRC), Lung Cancer, Other: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2014 – 2020

Global Cancer Diagnostics Market Set for Rapid Growth, To Reach Around USD 128.6 Billion by 2020

The report covers forecast and analysis for the cancer diagnostics market on a global and regional level. The study provides historic data of 2014 along with a forecast from 2015 to 2020 based revenue (USD Billion). The study includes drivers and restraints for the cancer diagnostics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the cancer diagnostics market on a global level.

In order to give the users of this report a comprehensive view on the cancer diagnostics. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the cancer diagnostics market has also been included. The study encompasses a market attractiveness analysis, wherein methods segments and application segments are benchmarked based on their market size, growth rate and general attractiveness.

The study provides a decisive view on the cancer diagnostics market by segmenting the market based on methods of diagnostics, applications and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2014 to 2020. Based on methods the market is segmented into tumor biomarker tests, imaging, endoscopy, and biopsy. Key application market covered under this study includes blood cancer, breast cancer, colorectal cancer (CRC), kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, and prostate cancer. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East and Africa with its further bifurcation into major countries including U.S. Germany, France, UK, China, Japan, India and Brazil. This segmentation includes demand for cancer diagnostics based on individual applications in all the regions and countries.

The report also includes detailed profiles of end players such as Abbott Laboratories, Inc., Ambry Genetics, AstraZeneca plc, bioMeriux SA, Eli Lilly and Company, Genoptix, Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Pfizer, Inc. The detailed description of players includes parameters such as company overview, financial overview, business and recent developments of the company.

This report segments the global cancer diagnostics market as follows:

Global Cancer Diagnostics Market: Methods Segment Analysis

  • Tumor Biomarker Tests
  • Imaging
  • Endoscopy
  • Biopsy

Global Cancer Diagnostics Market: Application Segment Analysis

  • Blood Cancer
  • Breast Cancer
  • Colorectal Cancer (CRC)
  • Lung Cancer
  • Others

Global Cancer Diagnostics Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • Germany
    • France
    • UK
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global cancer diagnostics market, 2014 – 2020 (USD Billion)
    • 2.2. Global cancer diagnostics market : Snapshot
  • Chapter 3. Cancer Diagnostics – Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global cancer diagnostics market drivers: Impact analysis
      • 3.2.2. Increasing prevalence of cancer
      • 3.2.3. Technological advancements
      • 3.2.4. Initiatives undertaken by governments and global health organizations to spread awareness about cancer
      • 3.2.5. Increasing number of private diagnostic centers
    • 3.3. Market restraints
      • 3.3.1. Global cancer diagnostics market restraints: Impact analysis
      • 3.3.2. Lack of sensitivity and specificity
      • 3.3.3. Risk of high radiation exposure used in different treatments
    • 3.4. Opportunities
      • 3.4.1. Safe cancer screening methods due to technology advancements
    • 3.5. Porter’s five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by methods segment
      • 3.6.2. Market attractiveness analysis, by application segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Cancer diagnostics Market – Competitive Landscape
    • 4.1. Company market share, 2014
    • 4.2. Price trend analysis
  • Chapter 5. Global Cancer diagnostics Market – Method Segment Analysis
    • 5.1. Global cancer diagnostics market: Method overview
      • 5.1.1. Global cancer diagnostics market revenue share, by method, 2014 and 2020
    • 5.2. Tumor Biomarker Tests
      • 5.2.1. Global tumor biomarker tests market, 2014 – 2020 (USD Billion)
    • 5.3. Imaging
      • 5.3.1. Global imaging market, 2014 – 2020 (USD Billion)
    • 5.4. Endoscopy
      • 5.4.1. Global endoscopy market , 2014 – 2020 (USD Billion)
    • 5.5. Biopsy
      • 5.5.1. Global biopsy market , 2014 – 2020 (USD Billion)
  • Chapter 6. Global Cancer diagnostics Market – Application Segment Analysis
    • 6.1. Global cancer diagnostics market: Application overview
      • 6.1.1. Global cancer diagnostics market revenue share, by application, 2014 and 2020
    • 6.2. Blood Cancer
      • 6.2.1. Global cancer diagnostics market for blood cancer, 2014 – 2020 (USD Billion)
    • 6.3. Breast Cancer
      • 6.3.1. Global cancer diagnostics market for breast cancer, 2014 – 2020 (USD Billion)
    • 6.4. Colorectal Cancer (CRC)
      • 6.4.1. Global cancer diagnostics market for colorectal cancer (CRC), 2014 – 2020 (USD Billion)
    • 6.5. Kidney Cancer
      • 6.5.1. Global cancer diagnostics market for kidney cancer, 2014 – 2020 (USD Billion)
    • 6.6. Liver Cancer
      • 6.6.1. Global cancer diagnostics market for liver cancer, 2014 – 2020(USD Billion)
    • 6.7. Lung Cancer
      • 6.7.1. Global cancer diagnostics market for lung cancer, 2014 – 2020 (USD Billion)
    • 6.8. Ovarian Cancer
      • 6.8.1. Global cancer diagnostics market for ovarian cancer, 2014 – 2020(USD Billion)
    • 6.9. Pancreatic Cancer
      • 6.9.1. Global cancer diagnostics market for pancreatic cancer, 2014 – 2020 (USD Billion)
    • 6.10. Prostate Cancer
      • 6.10.1. Global cancer diagnostics market for prostate cancer, 2014 – 2020 (USD Billion)
  • Chapter 7. Global Cancer diagnostics Market – Regional Segment Analysis
    • 7.1. Global cancer diagnostics market: Regional overview
      • 7.1.1. Global cancer diagnostics market revenue share, by region, 2014 and 2020
    • 7.2. North America
      • 7.2.1. North America cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.2.2. North America cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.2.3.2. U.S. cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.3.2. Europe cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.3.3. Germany
        • 7.3.3.1. Germany cancer diagnostics market revenue, by methods, 2014 – 2020, (USD Billion)
        • 7.3.3.2. Germany cancer diagnostics market revenue, by application, 2014 – 2020, (USD Billion)
      • 7.3.4. France
        • 7.3.4.1. France cancer diagnostics market revenue, by methods, 2014 – 2020, (USD Billion)
        • 7.3.4.2. France cancer diagnostics market revenue, by application, 2014 – 2020, (USD Billion)
      • 7.3.5. UK
        • 7.3.5.1. UK cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.3.5.2. UK cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific cancer diagnostics market revenue, by methods, 2014 – 2020, (USD Billion)
      • 7.4.2. Asia Pacific cancer diagnostics market revenue, by application, 2014 – 2020, (USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.4.3.2. China cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.4.4.2. Japan cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.4.5.2. India cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.5.2. Latin America cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
        • 7.5.3.2. Brazil cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa cancer diagnostics market revenue, by methods, 2014 – 2020 (USD Billion)
      • 7.6.2. Middle East and Africa cancer diagnostics market revenue, by application, 2014 – 2020 (USD Billion)
  • Chapter 8. Company Profile
    • 8.1. Abbott Laboratories, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Ambry Genetics
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. AstraZeneca plc
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. bioMeriux SA
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Eli Lilly and Company
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Genoptix, Inc.
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. GlaxoSmithKline plc
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. F. Hoffmann-La Roche Ltd.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Pfizer, Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments

Your Name (required)

Your Email (required)

Telephone Number (required)

Name of company (required)

Country Name (required)

How can we help you?

Prove You are Human (required)

captcha
Enter Capcha Image Properly